Measuring Effectiveness of Treatments in Rare Disorders, Evidence from Clinical Trials in Fragile X Syndrome

Author:

Steenbergen Adam V.1,Minhas Amrita1,Lin Tony1,Kaur Manpreet1,Bolduc Francois V.1

Affiliation:

1. University of Alberta

Abstract

Abstract Fragile X Syndrome (FXS) is the leading cause of inherited intellectual disability and autism spectrum disorder (ASD). It results from mutations of the FMR1 gene and the subsequent loss of Fragile X mental disorder 1 protein (FMRP). FXS has been the focus of intense preclinical research leading to several clinical trials. Effect sizes compare the effectiveness of treatments for neurodevelopmental disorders, such as FXS. This paper reviews effect sizes of different drug treatments in clinical trials for FXS to understand potential issues with the designs of current trials which could affect efficacy detectability. We searched for "Fragile X Syndrome" query in PubMed and filtered the clinical trials and downloaded the list of all publication IDs. PubMed's API was then utilized to collect the abstract's content into a spreadsheet. Studies were narrowed down to those with sufficient statistics data to calculate effect size relative to placebo. Phase 2 and 3 clinical trials for arbaclofen and one trial for L-acetylcarnitine reported large effect sizes. No significant findings were present between placebo and treatment groups. Studies without a placebo group reported larger treatment effect sizes. Small sample sizes, scarcity of studies, and outcome measures based on caregiver reports prevented us from drawing conclusions.

Publisher

Research Square Platform LLC

Reference42 articles.

1. Drugs for rare disorders;Cremers S;Br. J. Clin. Pharmacol.,2017

2. Fragile X syndrome: A review of clinical management;Lozano R;Intractable Rare Dis Res,2016

3. Fragile X syndrome: a review of associated medical problems;Kidd SA;Pediatrics,2014

4. Stone, W. L., Basit, H., Shah, M. & Los, E. Fragile X Syndrome. (StatPearls Publishing, 2023).

5. Fragile X syndrome;Hagerman RJ;Nat Rev Dis Primers,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3